Reviewing the literature on access to prompt and effective malaria treatment in Kenya: implications for meeting the Abuja targets

Table 1 Kenya's Current Malaria Treatment Policy

Condition	Recommendation	Dosage Form	Strength
Uncomplicated malaria (First-line treatment)	Artemether-lumefantrine	Tablet	20 mg Artemether + 120 mg Lumefantrine
Uncomplicated malaria (Second-line treatment)	Quinine	Tablet	200 mg 300 mg
Severe and complicated malaria
Pre-referral treatment	Artemether injection	Injection	Adult: 80 mg/ml
			Pediatric: 20 mg/ml
	Artesunate injection	Injection	60 mg/1 ml ampoule
	Artesunate rectal caps	Suppositories	100 mg
			400 mg
IV/IM phase	Quinine	Injection (IV or IM)	300 mg/1 ml ampoule
			600 mg/2 ml ampoule
Continuation phase	Quinine	Tablet	200 mg
			300 mg
Prevention of malaria in pregnancy	Intermittent Preventive Treatment (IPTp) using SP	Tablet	Sulphadoxine 500 mg; Pyrimethamine 25 mg
Treatment of uncomplicated malaria in pregnancy	Trimester 1: Quinine	Tablet	300 mg
	Trimester 2 & 3: Quinine or	Tablet	300 mg
	Artemether-Lumefantrine	Tablet	20 mg Artemether + 120 mg Lumefantrine
Treatment of complicated malaria in pregnancy	The treatment of pregnant women with severe malaria shall be the same as the treatment of severe malaria in the general population.

ISSN: 1475-2875